Issuer: | Eli Lilly and Company | ||
Principal Amount: | $600,000,000 | $400,000,000 | |
Maturity Date: | March 15, 2019 | June 15, 2044 | |
Coupon: | 1.950% per year | 4.650% per year | |
Public Offering Price: | 99.827% of principal amount | 99.861% of principal amount | |
Yield to Maturity: | 1.986% | 4.657% | |
Benchmark Treasury: | 1.500% due January 31, 2019 | 3.750% due November 15, 2043 | |
Spread to Benchmark Treasury: | T+45 bps | T+95 bps | |
Benchmark Treasury Price / Yield: | 99-26+ / 1.536% | 100-24+ / 3.707% | |
Interest Payment Dates: | March 15 and September 15, commencing September 15, 2014 | June 15 and December 15, commencing December 15, 2014 | |
Redemption Provisions: | |||
Make-whole call: | Make-whole plus 10 bps | Prior to December 15, 2043, make-whole plus 15 bps | |
Par call: | N/A | On or after December 15, 2043, at 100% | |
CUSIP / ISIN: | 532457 BF4 / US532457BF44 | 532457 BG2 / US532457BG27 | |
Trade Date: | February 20, 2014 | ||
Settlement Date: | February 25, 2014 (T+3) | ||
Ratings*: | Moody’s: A2; Standard & Poor’s: AA- | ||
Denominations: | $2,000 x $1,000 | ||
Joint Book-Running Managers: | Merrill Lynch, Pierce, Fenner & Smith Incorporated, Barclays Capital Inc., Citigroup Global Markets Inc. and Morgan Stanley & Co. LLC | ||
Co-Managers: | Drexel Hamilton, LLC and Loop Capital Markets LLC |